Please assess the completion status of the following clinical trial:

Trial Title: A Trial Comparing Treatment With Tiotropium Inhalation Capsules to Combivent Inhalation Aerosol in COPD Patients.

Study Design Characteristics:
- Allocation: None
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: None
- Phase: PHASE4
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria: Diagnosis of Chronic Obstructive Pulmonary Disease (COPD) Age: greater than or equal to 40 years~* Current or ex-smoker with a \>= 10 pack-year smoking history~* Use of Combivent® Metered Dose Inhaler (MDI)for \>= 1 month prior to Visit 1~Spirometric criteria (determined at study visits):~* Post-bronchodilator Forced Expiratory Volume in one second (FEV1) \<= 70% (Visit 1)~* Pre-bronchodilator FEV1 \<= 65% of predicted and FEV1/Forced Vital Capacity (FVC) \<= 70% (Visit 2)~Exclusion Criteria:~Clinical history of asthma~* History of thoracotomy with pulmonary resection~* History of Cystic Fibrosis, alpha 1 antitrypsin deficiency or interstitial lung disease~* Daytime use of oxygen therapy for \> 1 hour per day or if unable to abstain fr om using oxygen during Pulmonary Function Tests~* Any respiratory tract infection or COPD exacerbation in 6 weeks prior to Visit 1~* Recent history 6 months or less of Myocardial Infarction~* Unstable or life-threatening cardiac arrhythmias~* Hospitalization for Congestive Heart Failure during past year~* Malignancy for which patient is receiving chemo or radiation therapy~* Pregnant or nursing women~* Known hypersensitivity to ipratropium or carrier substances, including related food products such as soybean, peanuts, or lactose~* Use of SPIRIVA® 3 months prior to Visit 1~* Symptomatic of prostatic hypertrophy or bladder neck obstruction~* Known narrow- angle glaucoma~* Participating in a pulmonary rehab program within 4 weeks of Visit 1

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).